Furthermore, the acquisition order of the JAK2 V617F and additional non-driver mutations, such as in the TET2 gene, was shown to play a role in determining clinical MPN phenotypes [3,48,49]. The gene discussed is JAK2; the disease is myeloproliferative disorder.